

PERSONAL INFORMATION **Carla Herberts**

WORK EXPERIENCE

- April 2018- Present **representative at Committee for Advanced Therapies**
Medicines Evaluation Board (Netherlands)
Discuss and assess the quality, safety and efficacy of advanced therapy medicinal products (ATMPs)
- July 2014- Present **Senior Clinical assessor**
Medicines Evaluation Board (Netherlands)
Clinical assessment of oncology and hemato-oncology products.
Member of MEB advisory group on advanced therapies
- June 2011-June 2014 **Assessor**
Medicines Evaluation Board (Netherlands)
Farmacological-toxicological evaluations of medicinal products, advising the Medicine Evaluation Board of the Netherlands on non-clinical issues of registration of medicinal products.
- January 2006-June 2011 **Senior Non-clinical assessor**
National Institute of Public Health and the Environment (Netherlands)
Farmacological-toxicological evaluations of medicinal products, advising the Medicine Evaluation Board of the Netherlands on non-clinical issues of registration of medicinal products. .
- October 2001-December 2005 **Post-Doctoral fellow**
The Netherlands Cancer Institute (Netherlands)
Investigation of cell biological aspects of immune response

EDUCATION AND TRAINING

- February 1996-October 2001 **PhD**
Leiden University Medical Centre (Netherlands)

ADDITIONAL INFORMATION

- Expertise** oncology and hemato-oncology medicinal products, biotechnology derived medicinal products, advanced therapy medicinal products, immunological medicinal products and vaccines
- Publications** de Wilde, S., Guchelaar, H.-J., Herberts, C., Lowdell, M., Hildebrandt, M., Zandvliet, M., Meij, P. Development of cell therapy medicinal products by academic institutes (2016) Drug Discovery Today, 21 (8), pp. 1206-1212.
Herberts, C.A., Park, M.V.D.Z., Pot, J.W.G.A., de Vries, C.G.J.C.A. Results from a horizon scan on risks associated with transplantation of human organs, tissues and cells: from donor to patient (2015) Cell and Tissue Banking, 16 (1), 17 p.
Vestergaard, H.T., Apote, L.D., Schneider, C.K., Herberts, C. The evolution of nonclinical regulatory science: Advanced therapy medicinal products as a paradigm (2013) Molecular Therapy, 21 (9), pp. 1644-1648.

Herberts, C.A., Kwa, M.S.G., Hermsen, H.P.H. Risk factors in the development of stem cell therapy (2011) *Journal of Translational Medicine*, 9, art. no. 29, .

Herberts, C., Melgert, B., Van Der Laan, J.W., Faas, M. New adjuvanted vaccines in pregnancy: What is known about their safety? (2010) *Expert Review of Vaccines*, 9 (12), pp. 1411-1422.

Wijnhoven, S.W.P., Peijnenburg, W.J.G.M., Herberts, C.A., Hagens, W.I., Oomen, A.G., Heugens, E.H.W., Roszek, B., Bisschops, J., Gosens, I., Van De Meent, D., Dekkers, S., De Jong, W.H., Van Zijverden, M., Sips, A.J.A.M., Geertsma, R.E. Nano-silver - A review of available data and knowledge gaps in human and environmental risk assessment (2009) *Nanotoxicology*, 3 (2), pp. 109-138.

Van Der Laan, J.W., Herberts, C., Lambkin-Williams, R., Boyers, A., Mann, A.J., Oxford, J. Animal models in influenza vaccine testing (2008) *Expert Review of Vaccines*, 7 (6), pp. 783-793.

Reits, E.A., Hodge, J.W., Herberts, C.A., Groothuis, T.A., Chakraborty, M., Wansley, E.K., Camphausen, K., Luiten, R.M., De Ru, A.H., Neijssen, J., Griekspoor, A., Mesman, E., Verreck, F.A., Spits, H., Schlom, J., Van Veelen, P., Neefjes, J.J. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy (2006) *Journal of Experimental Medicine*, 203 (5), pp. 1259-1271.

Herberts, C.A., Neijssen, J.J., De Haan, J., Janssen, L., Drijfhout, J.W., Reits, E.A., Neefjes, J.J. Cutting edge: HLA-B27 acquires many N-terminal dibasic peptides: Coupling cytosolic peptide stability to antigen presentation (2006) *Journal of Immunology*, 176 (5), pp. 2697-2701.

Groothuis, T.A.M., Griekspoor, A.C., Neijssen, J.J., Herberts, C.A., Neefjes, J.J. MHC class I alleles and their exploration of the antigen-processing machinery (2005) *Immunological Reviews*, 207, pp. 60-76.

Neijssen, J., Herberts, C., Drijfhout, J.W., Reits, E., Janssen, L., Neefjes, J. Cross-presentation by intercellular peptide transfer through gap junctions (2005) *Nature*, 434 (7029), pp. 83-88.

Reits, E., Neijssen, J., Herberts, C., Benckhuijsen, W., Janssen, L., Drijfhout, J.W., Neefjes, J. A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation (2004) *Immunity*, 20 (4), pp. 495-506.

Herberts, C., Reits, E., Neefjes, J. Proteases, proteases and proteases for presentation (2003) *Nature Immunology*, 4 (4), pp. 306-308.

Jaye, A., Herberts, C.A., Jallow, S., Atabani, S., Klein, M.R., Hoogerhout, P., Kidd, M., Van Els, C.A.C.M., Whittle, H.C. Vigorous but short-term gamma interferon T-cell responses against a dominant HLA-A*02-restricted measles virus epitope in patients with measles (2003) *Journal of Virology*, 77 (8), pp. 5014-5016.

Herberts, C.A., Van Gaans-van den Brink, J., Van der Heeft, E., Van Wijk, M., Hoekman, J., Jaye, A., Poelen, M.C.M., Boog, C.J.P., Roholl, P.J.M., Whittle, H., De Jong, A.P.J.M., Van Els, C.A.C.M. Autoreactivity against induced or upregulated abundant self-peptides in HLA-A*0201 following measles virus infection (2003) *Human Immunology*, 64 (1), pp. 44-55.

Herberts, C.A., Meiring, H.M., Van Gaans-van den Brink, J.A.M., Van der Heeft, E., Poelen, M.C.M., Boog, C.J.P., De Jong, A.P.J.M., Van Els, C.A.C.M. Dynamics of measles virus protein expression are reflected in the MHC class I epitope display (2003) *Molecular Immunology*, 39 (10), pp. 567-575.

Herberts, C.A., Stittelaar, K.J., van der Heeft, E., van Gaans-van den Brink, J., Poelen, M.C.M., Roholl, P.J.M., van Alphen, L.J.W., Melief, C.J.M., de Jong, A.P.J.M., van Els, C.A.C.M. A measles virus glycoprotein-derived human CTL epitope is abundantly presented via the proteasomal-dependent MHC class I processing pathway (2001) *Journal of General Virology*, 82 (9), pp. 2131-2142..

Van Els, C.A.C.M., Herberts, C.A., Van Der Heeft, E., Poelen, M.C.M., Van Gaans-Van Den Brink, J.A.M., Van Der Kooi, A., Hoogerhout, P., Ten Hove, G.J., Meiring, H.D., De Jong, A.P.J.M. A single naturally processed measles virus peptide fully dominates the HLA-A*0201-associated peptide display and is mutated at its anchor position in persistent viral strains (2000) *European Journal of Immunology*, 30 (4), pp. 1172-1181.

Van Der Heeft, E., Ten Hove, G.J., Herberts, C.A., Meiring, H.D., Van Els, C.A.C.M., De Jong, A.P.J.M.

A Microcapillary Column Switching HPLC-Electrospray Ionization MS System for the Direct Identification of Peptides Presented by Major Histocompatibility Complex Class I Molecules (1998) *Analytical Chemistry*, 70 (18), pp. 3742-3751.

VanAerts, L.A.G.J.M., Poirot, C.M., Herberts, C.A., Blom, H.J., De Abreu, R.A., Trijbels, J.M.F., Eskes, T.K.A.B., Copius Peereboom-Stegeman, J.H.H., Noordhoek, J. Development of methionine synthase, cystathionine--synthase and S-adenosyl-homocysteine hydrolase during gestation in rats (1995) *Journal of Reproduction and Fertility*, 103 (2), pp. 227-232..

Projects

Memberships Member/participant of ILSI-HESI emerging issue Committee: Cell Therapy - TRACKing, Circulation, & Safety (CT-TRACS) Committee

Other Relevant Information